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ABSTRACT
Objective: A randomised controlled study performed
from 2007 to 2008 showed beneﬁcial effects of
a composite clinical pharmacist service as regards
a simple health status instrument. The present study
aimed to evaluate if the intervention was cost-effective
when evaluated in a decision-theoretic model.
Design: A piggyback cost-effectiveness analysis from
the healthcare perspective.
Setting: Two internal medicine wards at Sahlgrenska
University Hospital, Go ¨teborg, Sweden.
Participants: Of 345 patients (61% women; median
age: 82 years; 181 control and 164 intervention
patients), 240 patients (62% women, 82 years; 124
control and 116 intervention patients) had EuroQol-5
dimensions (EQ-5D) utility scores at baseline and at 6-
month follow-up.
Outcome measures: Costs during a 6-month
follow-up period in all patients and incremental
cost-effectiveness ratio per quality-adjusted life-year
(QALY) in patients with EQ-5D utility scores. Inpatient
and outpatient care was extracted from the VEGA
database. Drug costs were extracted from the Swedish
Prescribed Drug Register. A probabilistic analysis was
performed to characterise uncertainty in the cost-
effectiveness model.
Results: No signiﬁcant difference in costs between the
randomisation groups was found; the mean total costs
per individual6SD, intervention costs included, were
V10748613799 (intervention patients) and
V10344614728 (control patients) (p¼0.79). For
patients in the cost-effectiveness analysis, the
corresponding costs were V10912613999 and
V9290612885. Intervention patients gained an
additional 0.0051 QALYs (unadjusted) and 0.0035
QALYs (adjusted for baseline EQ-5D utility score).
These ﬁgures result in an incremental cost-
effectiveness ratio of V316243 per unadjusted
QALY and V463371 per adjusted QALY. The
probabilistic uncertainty analysis revealed that, at
a willingness-to-pay of V50000/QALY, the probability
that the intervention was cost-effective was
approximately 0.2.
Conclusions: The present study reveals that an
intervention designed like this one is probably not
cost-effective. The study thus illustrates that the
complexity of healthcare requires thorough health
economics evaluations rather than simplistic
interpretation of data.
INTRODUCTION
Up to about 50% of hospital admissions are
associated with drug-related problems
(DRPs),
1 and as a consequence, great
resources are spent on such problems. When
it comes to adverse drug reactions, a subset of
all DRPs that constitutes about 5% of hospital
admissions,
23only 20%e30% can be
prevented.
34Other DRPs include inappro-
priate prescribing, such as failures to select
the appropriate drug, route of administra-
tion, dosage or duration of treatment, based
on the patient’s medical history and
concomitant medication. These DRPs should
be possible to intervene and prevent, for
example by education,
5 although altering
prescribing behaviour may be a difﬁcult task.
A further example of a common DRP that
should be preventable is errors in patients’
medication information at transitions in
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ARTICLE SUMMARY
Article focus
- Clinical pharmacist services have been shown
beneﬁcial for patient health and healthcare costs,
although results are inconsistent. In the present
article, we present combined data on costs and
health outcomes for a composite clinical phar-
macist service.
Key messages
- Although our composite clinical pharmacist
service has previously been shown beneﬁcial as
regards a simple health status instrument, the
incremental cost-effectiveness ratio per QALY
was high, more than V460000 in the base case
and more than V100000 in most sensitivity
analyses.
Strengths and limitations of this study
- This study is the ﬁrst one to provide data on
costs per QALY for an in-hospital intervention
aimed to improve drug treatment. An important
limitation may be that the pharmacists acted like
external consultants rather than an integrated
part in healthcare, and further research on cost-
effectiveness of pharmacist services may be
called for.
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6e8 Taken together, DRPs in general need to be
prevented for a rational use of drugs and an efﬁcient
utilisation of healthcare resources.
One way to achieve rational use of drugs may be
through the use of clinical pharmacist services.
Such services may reduce DRPs
9 and increase patients’
health-related quality of life.
10 They may also affect the
rate of readmissions to hospital, although results are
inconsistent.
11 12
In a randomised controlled study performed by our
research group (http://clinicaltrials.gov identiﬁer:
NCT01016301),
13 we have reported positive effects of
a composite in-hospital clinical pharmacist service
(medication reviews, drug treatment discussion with the
patient at discharge and a medication report) on self-
rated health status as measured by the simple question
‘In your opinion, how is your state of health? Is it very
good, rather good, neither good nor bad, rather poor or
very poor?’ Health status was thus registered as an
integer from 1 (very poor) to 5 (very good), and at 6-
month follow-up, intervention patients had better self-
reported health than control patients as measured by
this question (mean6SD: 3.1460.87 vs 2.7760.94,
p¼0.020).
13 Clinical pharmacist services thus seem
favourable for patient health. In addition, they may not
cost too much, and they have even been suggested to
reduce costs,
11 although most economic evaluations
suffer from methodological limitations.
14
Taken together, the ﬁndings presented above may
intuitively lead to the conclusion that in-hospital clinical
pharmacist services are cost-effective. However, to the
best of our knowledge, no previous study has made an
attempt to combine data on costs and health outcomes
measured with the generic outcome measure quality-
adjusted life-years (QALYs) to calculate cost per QALY
gained. Such data should be of value to healthcare
decision makers, as they allow comparisons between
interventions and thus facilitates prioritisation among
interventions. Thus, the aim of the present study was to
analyse if the composite in-hospital clinical pharmacist
service in our previous study
13 was cost-effective.
METHODS
The study was of a ‘piggyback’ bottomeup design, in
which resource use was measured in the context of
a randomised controlled study primarily designed to
investigate efﬁcacy. The study was performed in two
internal medicine wards at Sahlgrenska University
Hospital/Mo ¨lndal situated in Region Va ¨stra Go ¨taland in
Sweden, and the details have been reported elsewhere.
13
The composite intervention consisted of (1) medication
reviews including feedback on prescribing to physicians;
(2) drug treatment discussion with the patient at
discharge and (3) a medication report including
a summary of the drug treatment changes during the
hospital stay and a medication list, given to the patient
and sent to the patient’s general practitioner (GP) at
discharge. The medication reviews aimed to identify
potential DRPs and did not focus on reducing costs.
Patients in the control group received normal care. The
study complies with the Declaration of Helsinki and was
approved by the Regional Ethical Review Board. Written
informed consent was obtained from all patients before
inclusion.
Costs
Costs during a 6-month follow-up period were analysed
in all patients included in the randomised controlled
study. In the analysis, a healthcare perspective was
applied. Thus, all direct costs were included in the
analysis, that is, costs for the intervention, inpatient and
outpatient care and reimbursed drugs.
The costs for the intervention were estimated based on
costs for working time for an in-hospital pharmacist, and
time consumption for each part of the intervention was
counted separately.
All healthcare consultancies during the 6-month
follow-up were extracted from a regional database
(VEGA database), which contain information on all
inpatient and outpatient care in the Region Va ¨stra
Go ¨taland. The number of bed-days at hospital wards was
extracted, as was the number of outpatient consultancies
in the categories GP, specialist (including emergency
department visits), nurse, and other that included all
other professionals. End of follow-up was 6 months after
discharge from the hospital, and only bed-days and
outpatient care within this period were included in the
analysis. All direct costs were estimated by combining the
resource usage data with unit costs for Sweden obtained
from public sources (inpatient care: V777 per bed-day;
outpatient care: V144 per GP visit, V518 per specialist
visit, V55 per nurse visit and V58 per visit for other
professionals).
In Sweden, the majority of costs for drugs are reim-
bursed by the society. Costs for drugs were extracted
from the Swedish Prescribed Drug Register, which
contains individualised data on all prescribed and
dispensed drugs including costs. The reimbursed costs
for all drugs dispensed during the 6-month follow-up
were summarised for each patient.
Effectiveness
The effectiveness of the intervention was estimated as
gain in QALYs. Data on health-related quality of life were
gathered by means of EuroQol-5 dimensions (EQ-5D)
self-report questionnaires,
15 which were ﬁlled in at
inclusion and at 6-month follow-up. Deceased patients
were assigned an EQ-5D utility score of ‘0’ at 6 months,
the predeﬁned quality-of-life weight for the health state
‘dead’ in this instrument.
For each individual, QALYs were calculated with the
established area under the curve approach, that is, the
change in QALY weight is assumed to occur linearly
between the measurements.
16 Thus, the unadjusted
difference in QALYs between the randomisation groups
was calculated as the mean difference between EQ-5D
utility scores (6-month value minus baseline value),
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with 2 (to obtain area under the curve for a triangular
area). In addition, adjusted differences in QALYs were
calculated since future utility scores are correlated with
baseline utility scores and this may be a source of bias.
Indeed, even in trials with large sample sizes, there will
usually be an imbalance between arms regarding base-
line utility score.
17 To obtain adjusted differences in
QALYs between the randomisation groups, linear
regression analysis was performed to calculate the
difference between EQ-5D utility score at 6-month
follow-up adjusted for baseline EQ-5D utility score.
17
This ﬁgure was then multiplied with 0.5 and divided
with 2, as described above.
Cost-effectiveness analysis
The cost-effectiveness (or, more properly, costeutility)
analysis was applied to the subset of patients where EQ-
5D utility scores were available at baseline and at
6-month follow-up. All direct costs for these patients
were included in the analysis, that is, costs for the
intervention, inpatient and outpatient care, and
reimbursed drugs.
Probabilistic uncertainty analysis
A probabilistic analysis with Monte Carlo simulations was
performed to characterise uncertainty in the cost-effec-
tiveness model.
18 In each simulation, parameter values
were drawn randomly from the deﬁned probability
distributions. g-Distributions were used both for costs
and for (dis)utilities. The cohort of hypothetical indi-
viduals was then run through the model, and mean costs
and health outcomes were calculated for both interven-
tion and control strategies. This procedure was repeated
5000 times, generating 5000 estimates of mean costs and
mean effects. The results were presented as a cost-
effectiveness acceptability curve, which shows the
probability that the intervention was cost-effective at
different levels of willingness-to-pay. The model was run
in TreeAge Pro software (TreeAge Software Inc.
Williamstown, Massachusetts, USA).
Sensitivity analysis
The costs for patients at the end of life are generally
high, and therefore we performed a sensitivity analysis of
the cost-effectiveness separately for patients alive and
deceased at 6 months. Furthermore, many observations
were missing for EQ-5D at 6-month follow-up. In the
cost-effectiveness analysis described above, these patients
were excluded. This is problematic since it means that
a substantial amount of information is lost, and the
results may thus be biased.
19 We therefore performed
a sensitivity analysis with imputed values for missing data,
that is, a cost-effectiveness analysis in all 345 patients.
These values were imputed in a regression model, in
which we included the variables randomisation group,
age, sex, EQ-5D utility scores at baseline and at 6-month
follow-up and total costs. Five sets of data were created
(multiple imputation) and pooled results on EQ-5D
utility scores were used to estimate unadjusted and
adjusted gain in QALYs.
Statistics
Statistical analyses were performed with SPSS V.17.0. All
costs are presented in Euro (V)( V1¼8.94 Swedish
crowns, V1¼1.43 US dollars ($) (19 April 2011)).
Student t test was used for comparisons between groups;
this method is considered most appropriate for health
economics analysis although skewed distribution can be
expected.
20 Where appropriate, values are presented
both as mean6SD and median (IQR) to illustrate the
skewed distribution. The study had a short time span,
and costs were therefore not discounted.
RESULTS
Costs
A total of 345 patients (60.9% women, 81.5
(73e85) years) were included in the analysis of costs: 181
in the intervention group and 164 in the control group
(ﬁgure 1). There were no signiﬁcant differences in
baseline characteristics between the randomisation
groups (table 1).
The cost per work hour of a pharmacist was estimated
at V66.3 assuming 1250 clinical pharmacy work hours
per year and a salary of V3915 per month plus
employer’s fee (45% of the salary) and 20% overhead
costs. The three pharmacists who performed the inter-
vention estimated the time for each part of the inter-
vention to 0.5 h (medication review), 0.25 h (feedback to
physician), 0.20 h (patient discussion) and 1.5 h (medi-
cation report). These estimates include time for gath-
ering information that was missing in the medical
records as well as time for discussions and conﬁrmations
with the responsible physician. In all, 162 out of 164
intervention patients received medication reviews, 92 of
which were fed back to the physicians, 97 patients
received drug treatment discussion at discharge and 137
patients received a medication report. With these esti-
mates and results, the costs per intervention patient were
V133641 (146 (133e163)).
Figure 1 Flowchart of the study population.
EQ-5D, EuroQol-5 dimensions.
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Analysis of an in-hospital clinical pharmacist serviceInpatient and outpatient care during the 6-month
follow-up is presented in table 2. No signiﬁcant differ-
ences were found between the groups. The distribution
of costs per patient is illustrated in ﬁgure 2. A total of
354 occasions of in-hospital care were identiﬁed in 171
patients during the 6-month follow-up: 173 (82 patients)
and 181 (89 patients) in the intervention and the
control group, respectively. A total of 4038 outpatient
visits were performed by 327 patients during the
6-month follow-up: 1788 (156 patients) and 2250 (171
patients) in the intervention and the control group,
respectively.
The costs per patient for healthcare consumption and
drugs during the 6-month follow-up are presented in
table 3. No signiﬁcant differences in costs between the
randomisation groups could be detected; the total costs
per patient, intervention costs included, were
V10748613799 (4898 (1990e14308)) for intervention
patients and V10344614728 (1589 (4146e14110)) for
control patients (p¼0.79).
Sensitivity analysis revealed that total costs for
patients alive at 6 months were V9623612093 (4491
(1810e12548)) for intervention patients and
V9364613596 (3455 (1515e10626)) for control patients.
The corresponding ﬁgures for patients deceased within
6m o n t h s w e r e V2078964432 (11162 (4482e26206))
for intervention patients and V2150465376 (13186
(7941e27622)) for control patients.
Cost-effectiveness analysis
A total of 240 patients (62.1% women, 82
(75e86) years) were included in the cost-effectiveness
analysis (ﬁgure 1). Six months after discharge from
hospital, 38 patients were deceased: 22 and 16 in the
intervention and the control group, respectively. There
were no signiﬁcant differences in baseline characteristics
between the randomisation groups (table 1).
EQ-5D utility scores at baseline and 6-month follow-up
are presented in table 4. With these ﬁgures, the inter-
vention patients gained an additional 0.0051 unadjusted
QALYs compared with control patients. When adjusted
for baseline EQ-5D, the corresponding ﬁgure was 0.0035
adjusted QALYs.
Inpatient and outpatient care as well as direct costs in
the randomisation groups are presented in tables 2 and
3. The total costs per patient, intervention costs
included, were V10912613999 (4995 (2102e13974))
and V9290612885 (3514 (1437e12098)) for interven-
tion and control patients, respectively. These ﬁgures
result in an incremental cost-effectiveness ratio of
V316243 per unadjusted QALY and V463371 per
adjusted QALY.
The probability that the intervention was cost-effective
at the usual thresholds below say V50000/QALY was
approximately 0.2, which is shown in ﬁgure 3.
Sensitivity analysis revealed that 0.0063 unadjusted and
0.0091 adjusted extra QALYs were gained in intervention
Table 1 Patient characteristics in the randomisation groups
All patients
Patients with EQ-5D utility
scores at baseline and at
6-month follow-up
Intervention
(n[164)
Control
(n[181)
Intervention
(n[116)
Control
(n[124)
Age, years 81 (72e87) 82 (75e86) 82 (72e87) 82 (76e85)
Female sex 98 (60) 110 (61) 71 (61) 78 (63)
Length of stay in hospital, days 6 (4e10) 6 (4e10.5) 7 (5e10.75) 6.5 (4e11)
Regularly prescribed drugs at admission, n 7 (4e9) 7 (4e10) 7 (4e10) 7.5 (4.25e10)
Prescribed drugs as needed at admission, n 1 (0e2) 1 (0e3) 1 (0e2) 1 (0e3)
Values are presented as median (IQR) or n (%).
EQ-5D, EuroQol-5 dimensions.
Table 2 Inpatient and outpatient care during the 6-month follow-up
All patients
Patients with EQ-5D utility scores at baseline
and at 6-month follow-up
Intervention (n[164) Control (n[181) Intervention (n[116) Control (n[124)
Inpatient care (bed-days) 0 (0e12.75) 10.0616.8 0 (0e12) 9.4617.8 1.5 (0e13.5) 10.2617.1 0 (0e11.75) 8.2615.4
Outpatient care (visits)
Total 7 (3e16.75) 10.9611.2 8 (4e14) 12.4616.5 7 (3e14.5) 11.0612.2 8 (4e14) 11.2612.2
GP 1 (0e3) 1.862.1 1 (0e3) 1.861.9 1 (0e2.75) 1.862.0 2 (1e3) 1.961.9
Specialist 2 (1e4) 2.862.7 2 (1e4) 2.962.9 2 (1e4) 2.762.6 2 (1e4) 2.862.9
Nurse 1 (0e6) 4.768.5 2 (0e5) 5.7614.3 1 (0e7) 4.969.5 2 (0e5) 4.569.5
Other 0 (0e1) 1.763.8 0 (0e2) 2.064.0 0 (0e1) 1.664.1 0 (0e2) 2.063.9
Values as presented as median (IQR) and mean6SD.
EQ-5D, EuroQol-5 dimensions; GP, general practitioner.
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Analysis of an in-hospital clinical pharmacist servicepatients alive at 6-month follow-up. The total costs per
patient were V9250611402 (4529 (2051e11449)) and
V7637610229 (2914 (1417e9928)) for intervention
and control patients, respectively, resulting in V254415
per QALY and V178137 per adjusted QALY. The
corresponding ﬁgures for deceased patients were 0.030
unadjusted QALYs gained in the intervention patients,
V18014620789 (11162 (4482e26206)) (intervention
patients) and V20448621504 (13186 (7941e27622))
(control patients), resulting in V80601 saved per QALY
in intervention patients.
Sensitivity analysis in all patients, with multiple impu-
tation for missing data, revealed that 0.0024 unadjusted
and 0.0035 adjusted extra QALYs were gained in the
intervention patients, resulting in a cost of V166566 per
unadjusted QALY and V115181 per adjusted QALY.
DISCUSSION
The present study reveals that a composite clinical
pharmacist intervention designed like this one is prob-
ably not cost-effective. This is surprising since the inter-
vention in itself is not particularly costly and has been
shown beneﬁcial as regards a simple and understandable
health status instrument.
13 Moreover, we were surprised
by our ﬁndings since we expected the intervention to
reduce hospital visits as previously reported.
11 On the
contrary, our intervention seems to lead to increased
healthcare costs. This coupled with a modest non-
signiﬁcant effect on the health outcome as measured by
EQ-5D, which may be a less sensitive health status
instrument than a simple health state question, leads to
high costs per QALY gained. The study thus illustrates
that the complexity of healthcare requires thorough
health economics evaluations on joint distribution of
differences in costs and effects rather than simplistic
interpretation of data, and choice of outcome measures
may affect the results.
There may be several explanations for our ﬁndings.
First, our study was performed in a pharmacist-naive
Figure 2 Distribution of costs per patient.
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Analysis of an in-hospital clinical pharmacist servicesetting with relatively inexperienced pharmacists. This
study setting holds the advantage that it gives a realistic
picture on what to expect when introducing pharmacists
as external consultants in hospital wards, information
which ought to be of value for healthcare decision
makers. It also enables a control group that receives
normal care; this may be more difﬁcult in settings where
clinical pharmacist services are already available. On the
other hand, the study setting does not allow time for the
new profession to integrate in the healthcare, and this
may have negatively affected the results. Thus, our
results do not necessarily apply to established clinical
pharmacist services, and we encourage further studies to
investigate the cost-effectiveness of such services in
healthcare.
Second, the content of the clinical pharmacist service
may affect the results. At one end, it could consist of
a passive review of the prescribed drugs, using standard
decision support systems to identify possible drugedrug
and drugepatient interactions, while at the other, it
might comprise an active participation in medication
reconciliation and medication management decisions.
Indeed, medication review alone does not affect the rate
of further hospital admissions (RR (95% CI) 0.99 (0.87
to 1.14)),
12 whereas the opposite has been shown for
a composite clinical pharmacist service.
11 In our study,
we evaluated a composite clinical pharmacist interven-
tion described in the Methods section. However, the
pharmacists did not take part in the rounds, as opposed
to the study by Gillespie et al,
11 where favourable effects
of a composite clinical pharmacist intervention were
reported. When designing our intervention, we consid-
ered attending the rounds too time-consuming for the
pharmacists, and therefore we chose against this.
Nevertheless, we believe that this decision may have
negatively affected the results since it may have delayed
the integration of the new profession in healthcare, and
further research on pharmacist services designed differ-
ently from ours may therefore be needed. Moreover, the
extent of implementation of the separate parts of our
intervention varied, and it would be of value to further
explore if speciﬁc parts of pharmacist interventions are
cost-effective. Indeed, it has recently been pointed out in
a Cochrane review that heterogeneity in study compar-
ison groups, outcomes and measures makes it difﬁcult to
draw generalised conclusions on effects of pharmacist
interventions.
21
Third, estimates of costs may inﬂuence the results. In
our study, the use of healthcare resources was measured
under real-world conditions as is often recommended
22;
costs were not protocol-driven, and only costs after
discharge were included, that is, after the intervention
was concluded. In addition, costs were evaluated in
a comprehensive manner from a healthcare perspective;
we included costs for bed-days, outpatient consultancies
and reimbursed drugs. When only number of hospital
visits at a single hospital is included in the analysis as in
the study by Gillespie et al,
11 costs may be under-
estimated. Indeed, we found that intervention patients
spent numerically more days in hospital during the 6-
month follow-up period, and this may have inﬂuenced
the results since in-hospital care is expensive as
compared with outpatient care. One may speculate that
an intervention like ours, which aim to increase patient
and health professional awareness on health matters
such as drug treatment and adverse reactions, may
increase consumption of healthcare.
Fourth, length of follow-up may affect the results. A
short-term increase in healthcare utilisation may, for
example, lead to lower utilisation in the long term. We
chose a 6-month follow-up since we believed that the
beneﬁts of the intervention would accrue within this
time span. Changes in prescribed drugs often occur at
healthcare consultancies and we expected the patient
group to have many healthcare consultancies. Thus, the
effects of the intervention would diminish by time, and
we considered 6 months an appropriate length of follow-
up. Nevertheless, it cannot be ruled out that this choice
may have affected the results, for example, by affecting
long-term QALY gain, and we encourage further studies
with longer follow-up periods.
More patients in the intervention group died before
6-month follow-up. We cannot present a plausible
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Figure 3 Cost-effectiveness acceptability curve.
Table 4 Health-related quality of life as measured with
EQ-5D utility score
Intervention
(n[116)
Control
(n[124)
EQ-5D utility score
Baseline 0.39660.382 0.40760.344
6-month follow-up 0.38560.362 0.37660.375
EQ-5D difference  0.01160.437  0.03160.369
Values are presented as mean6SD.
EQ-5D, EuroQol-5 dimensions.
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would expect that a higher quality in prescribed drugs,
an increased awareness of drugs in patients and an
improved communication of drug treatment between
hospital and primary care would be favourable. One
may speculate, however, that the pharmacist intervention
resulted in patients being either taken off medication
that they would beneﬁt from or that doses were
reduced below the clinically optimal level in an effort to
reduce harmful side effects or drug interactions.
However, few changes in prescribed drugs were made
due to the ﬁrst part of the intervention, that is, the
pharmacist recommendations on modiﬁcations in
drug therapy,
13 and we deem these unlikely to have
had a major impact on patient health. Probably, the
observed difference in deaths occurred by chance, but
irrespective of the causality of the deaths, these nega-
tively affected the number of QALYs gained in the
intervention group.
Sensitivity analysis revealed that the pharmacist inter-
vention may be cost saving for terminal patients. These
results raise the hypothesis that clinical pharmacist
interventions could be cost-effective for subgroups of
patients, for example, those who cost most. Indeed,
interventions targeting such patients may have great
implications on healthcare costs; the majority of
healthcare resources are spent on a small proportion of
all patients,
23 a fact that is also illustrated by the skewed
distribution of costs in the present study.
An important limitation of the present study is the
high degree of exclusion of patients as described in the
original paper; 66% of patients admitted to the wards
were deemed ineligible for inclusion by the ward physi-
cian or nurse since the design of the study required
patients to be capable of discussing drug treatment and
assessing their health status.
13 This may make the results
less applicable to a general patient population. On the
other hand, this exclusion criterion may make the results
more naturalistic; before a pharmacist approaches
a patient, it would seem natural to ask the ward
personnel if the patient is appropriate to intervene.
Furthermore, EQ-5D values were not available for all
patients, and analysis on patients with complete data
only may have introduced bias.
19 However, when
imputing values for these patients in a sensitivity analysis,
the cost per QALY gained was still high.
In addition, the in-hospital setting of our
intervention may be questioned since the majority of
prescribing decisions occur in outpatient settings.
However, our choice of setting was based on several
assumptions: (1) in Sweden, patients are hospitalised
only if really ill, and thus we regarded such patients to be
at high risk of DRPs and likely to beneﬁt from the
intervention; (2) we considered transition from inpa-
tient to outpatient settings a major area of concern,
and (3) a hospital setting provided a more practical
means to implement an intervention than an outpatient
setting. Indeed, a low probability of cost-effectiveness has
been shown for medication reviews in an outpatient
setting.
24
Another limitation of the present study is that no
signiﬁcant differences in costs could be found. However,
very large sample sizes would be required to obtain p
values <0.05 since the distribution of costs is skewed.
Health economists therefore advocate that the likeli-
hood that the intervention is cost-effective should be
assessed,
22 as done in the present study, shown in the
cost-effectiveness acceptability curve.
A further limitation is that a cost-effectiveness analysis
from a healthcare perspective does not include costs for
productivity loss. Indeed, 17 intervention patients and 24
control patients were <65 years of age,
13 and an analysis
of cost-effectiveness from a societal perspective may thus
differ somewhat from the present results. However, we
believe that a healthcare perspective is most relevant
for a hospital-based intervention like this one. Further-
more, this perspective probably includes the majority of
costs and beneﬁts associated with the intervention, and
we believe that a societal perspective would have led to
quite similar results, particularly since the majority of
patients were very old and do thus not have any
productivity loss.
CONCLUSIONS
The present study reveals that a composite clinical
pharmacist intervention designed like this one, when
applied to a relatively heterogeneous population of
predominantly older patients, is probably not cost-
effective. This is surprising since the intervention is not
costly and has been shown beneﬁcial as regards a simple
and understandable health status instrument, and we
even expected the intervention to save costs from
a healthcare perspective. The study thus illustrates that
the complexity of healthcare requires thorough health
economics evaluations rather than simplistic interpreta-
tion of data. Healthcare decision makers may ﬁnd the
results of interest when considering if and how to
introduce pharmacist services.
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